Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 16196
Sealed predictions
- BTBD10 in dopamine neurons, braak+0.05 (p 0.892) → +0.84 (p 0.005)receipt 16203
Swarm cases
receipt 16203: BTBD10 in dopamine neurons, braak
- power
- full sample +0.52 (p 0.027, n 18), 95% CI +0.07 to +0.79. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.60 (p 0.0080, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.75 (p 3.5e-4, n 18). not the mix.
- skeptic
- leave-one-out range +0.46 to +0.72, sign flips 0; without severely affected donors +0.52 (p 0.027, n 18). robust.
- cell type
- strongest in microglia: +0.62 (p 0.0062, n 18) vs +0.52 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for BTBD10 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up BTBD10 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.15 p 0.594 (needs p < 1.4e-4)
Receipts
loading the receipts